Lipids and nanoparticle compositions thereof

Inventors

Stanton, Matthew G. • Nolting, Birte

Assignees

Generation Bio Co

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12252470-B2

Patent

Publication Date

2025-03-18

Expiration Date


Abstract

Provided herein are lipids having the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

Core Innovation

The disclosure relates to an ionizable lipid represented by Formula (I) and pharmaceutically acceptable salts thereof, where a is an integer from 1 to 20 and b is an integer from 2 to 10. The lipid includes an R1 group that is absent or selected from (C2-C20)alkenyl, —C(O)O(C2-C20)alkyl, and cyclopropyl substituted with (C2-C20)alkyl, and an R2 group defined as (C2-C20)alkyl.

The disclosure provides exemplary ionizable lipids as Lipids 1–20 in Table 3, each represented by chemical structures and/or names, and further defines additional chemical embodiments using Formula (Ia), (Ib), and (Ic) with variable substituent groups including Rq, Rz, a, b, R1, and R2. The defined integer parameters a and b and the selection constraints for R1 and R2 establish the chemical scope for the ionizable lipids disclosed.

The disclosure states that lipid nanoparticles comprising the disclosed ionizable lipids and a capsid-free, non-viral DNA vector can be used for delivery, and also describes an LNP/capsid-free ceDNA delivery platform using the ionizable lipids. The described studies evaluate ceDNA-luc expression/activity after formulation as LNPs with various disclosed lipids, compared to SS-OP (COATSOME SS-OP), and present in vivo studies with imaging by IVIS and luciferase expression/activity measurements.

The document also discloses multi-step synthesis of disulfide-containing lipid series members and related intermediates, including disulfide-containing intermediates, protected phenylacetic acid derivatives, disulfide bis-phenylacetates, hydroxyl phenylacetates, and fatty-acid chain fragments installed by esterification to form nonanedioate and related lipids. The disclosed work is framed around the lipid structural series represented by Formula (I) in the claims, with pharmaceutically acceptable salts also included.

Claims Coverage

The independent claims cover a Formula (I) lipid with specified integer and substituent constraints, and a specific named lipid, Lipid 7, each including a pharmaceutically acceptable salt option. Overall, the claim set emphasizes defined chemical-structure scope and explicit enumeration of exemplars for the lipid family.

Formula (I) lipid with constrained integers and substituent selection

A lipid represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein a is an integer ranging from 1 to 20, b is an integer ranging from 2 to 10, R1 is absent or is selected from the group consisting of (C2-C20)alkenyl, —C(O)O(C2-C20)alkyl, and cyclopropyl substituted with (C2-C20)alkyl, and R2 is (C2-C20)alkyl.

Specific Lipid 7 structure

A lipid wherein the lipid is Lipid 7 represented by the following structure, or a pharmaceutically acceptable salt thereof.

Discrete refinement of lipid parameters using additional formula integers

c and d are each independently integers from 1 to 8 for the lipid represented by Formula (II).

Narrowed b range in dependent scope

b is an integer ranging from 3 to 9, or from 5 to 7.

R1 constrained to specific ester-alkyl variants with unbranched alkyl

R1 is -C(O)O(C2-C20)alkyl, -C(O)O(C4-C18)alkyl, -C(O)O(C4-C12)alkyl, or -C(O)O(C4-C10)alkyl, where the alkyl is unbranched.

R1 constrained to specific ester-alkyl variants with branched alkyl

R1 is -C(O)O(C4-C18)alkyl, -C(O)O(C4-C12)alkyl, or -C(O)O(C4-C10)alkyl, and the alkyl is a branched alkyl.

Enumerated lipid exemplars in a table

The lipid of the claim is selected from Lipid 1 through Lipid 20 in Table 3, including pharmaceutically acceptable salts.

The claim coverage centers on a lipid defined by Formula (I) with specified integer ranges for a and b, a selectable R1 substituent set or absence of R1, and R2 as (C2-C20)alkyl. Dependent claims further narrow the scope by adding c and d parameters, restricting b to specific ranges, constraining R1 to specific ester-alkyl chain-length options with unbranched or branched alkyl conditions, and optionally restricting to Lipid 1–20 exemplars in Table 3.

Stated Advantages

LNPs formulated with various disclosed lipids yield equivalent or higher luciferase expression/activity than SS-OP controls.

LNPs are generally better tolerated, including observations such as less body-weight loss.

Documented Applications

Delivery using lipid nanoparticles comprising the disclosed ionizable lipids and a capsid-free, non-viral DNA vector.

A capsid-free ceDNA delivery platform using lipid nanoparticles (LNPs) loaded with TNA, including ceDNA (closed-ended linear duplex DNA), with ionizable lipids as described.

ceDNA-loaded lipid nanoparticles formulated for evaluating luciferase expression/activity from ceDNA-luc and imaging by IVIS in in vivo studies compared to SS-OP (COATSOME SS-OP).

Condensation or encapsulation of nucleic acid at low pH using ionizable, cationic, and non-fusogenic ionizable lipids, with optional non-cationic helper lipids to increase fusogenicity and stability.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.